Loading…
BOOTS ADULT ALLERGY AND HAYFEVER RELIEF is a brand name for Beclomethasone (also known as Beclometasone). The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Perrigo Hayfever Relief 50 micrograms/spray Nasal Spray is indicated for the prevention and treatment of allergic rhinitis, including hayfever, in adults aged 18 and over. Perrigo Hayfever Relief 50 micrograms/spray Nasal Spray provides symptomatic relief from nasal congestion, runny nose, sneezing, itchy nose, eye…
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults aged 18 and over:
The recommended dosage is two sprays into each nostril morning and evening (400 micrograms/day). Once control has been established, it may be possible to maintain control with fewer sprays. A dosage regimen of one spray into each nostril morning and evening has been shown to be efficacious in some patients.
However, should the symptoms recur, patients should revert to the recommended dosage of two sprays into each nostril morning and evening. The minimum dose should be used at which effective control of symptoms is maintained. Total daily administration should not exceed eight sprays (400 micrograms).
Perrigo Hayfever Relief 50 micrograms/spray Nasal Spray quickly starts to reduce inflammation and swelling in the nose. But for best effect patients should start to use Perrigo Hayfever Relief 50 micrograms/spray Nasal Spray two or three days before they expect to get symptoms to prevent them from developing.
For full therapeutic benefit Perrigo Hayfever Relief 50 micrograms/spray Nasal Spray should be used regularly. If symptoms have not improved after 14 days treatment, medical advice must be sought. Paediatric population Perrigo Hayfever Relief 50 micrograms/spray Nasal Spray is not recommended for children or adolescents under 18 years of age.
Method of Administration Perrigo Hayfever Relief 50 micrograms/spray Nasal Spray is for administration by the intranasal route only.
Other brands of Beclomethasone in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Adverse reactions listed below are based on clinical trial data and classified according to MedDRA frequency and System Organ Class.
Frequency categories are defined according to the following convention:
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). 4) Immune system disorders Very rare: hypersensitivity reactions including rashes, urticaria, pruritus, erythema, oedema of the eyes, face, lips and throat, anaphylactoid / anphylactic reactions, dyspnea and/or bronchospasms.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the MHRA Yellow Card Scheme.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Systemic effects of nasal corticosteroids may occur, particularly at high doses when used for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations.
Potential systemic effects may include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).
Treatment with higher than recommended doses may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
This product should not be used continuously for longer than 3 months without consulting a doctor. Infections of the nasal passages and paranasal sinuses should be appropriately treated but do not constitute a specific contra-indication to treatment with Perrigo Hayfever Relief 50 micrograms/spray Nasal Spray.
Although Perrigo Hayfever Relief 50 micrograms/spray Nasal Spray will control seasonal allergic rhinitis in most cases, an abnormally heavy challenge of summer allergens may, in certain instances, necessitate appropriate additional therapy particularly to control eye symptoms.
Perrigo Hayfever Relief 50 micrograms/spray Nasal Spray contains 20 micrograms Benzalkonium chloride in each 100 mg spray, which may cause bronchospasm and local reactions. Medical advice should be sought before using Perrigo Hayfever Relief 50 micrograms/spray Nasal Spray by patients using other forms of corticosteroid treatments such as asthma medications, tablets, injections, similar nasal sprays, eye or nose drops, creams, ointments.
Benzalkonium chloride may cause irritation or swelling inside the nose, especially if used for a long time. Visual disturbances Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
1.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.